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httpImpaired renal function is associated with mortality
and morbidity after endovascular abdominal aortic
aneurysm repair
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Background: Renal function may be associated with poor outcome following endovascular abdominal aortic aneurysm
repair (EVAR), but this relationship has not been adequately investigated. The aim of this study is to evaluate the
association of estimated glomerular ﬁltration rate (eGFR) with cardiovascular events and all-cause mortality after EVAR.
Methods: Prospective cohort study of patients undergoing elective EVAR; eGFR was calculated using the Chronic Kidney
Disease Epidemiology Collaboration formula, and patients were divided in four groups (eGFR $90 mL/min/1.73 m2,
group 1; 60-89, group 2; 30-59, group 3; <30, group 4). Composite end point consisted of death, nonfatal myocardial
infarction, stroke, and vascular complications. Kaplan-Meier curves were constructed, and between-group comparisons
were performed adjusted for variables that differed at baseline.
Results: A total of 383 patients (mean age, 69 6 8 years; mean abdominal aortic aneurysm diameter, 6.2 6 1.4 cm) were
included. Over a mean follow-up of 34 6 12 months, the following events occurred: 20 deaths (5.2%), 15 nonfatal
myocardial infarctions (3.9%), 9 nonfatal strokes (2.3%), and 7 peripheral vascular complications (1.8%). Patients with
an eGFR <30 had the highest mortality (35%) and incidence of complications (80%) as per the end point (P[ .009 and
P < .001, respectively). Adjusted Cox-regression analysis showed that a higher eGFR at baseline by 1 mL/min/1.73 m2
was associated with a 5% lower likelihood of complications as per the end point (P < .001; hazard ratio, 0.95; 95% con-
ﬁdence interval, 0.94-0.97) and a 6% lower likelihood of death (P < .001; hazard ratio, 0.94; 95% conﬁdence interval,
0.92-0.97).
Conclusions: Impaired renal function is associated with an increase in cardiovascular events and mortality following
elective EVAR. (J Vasc Surg 2013;58:879-85.)Abdominal aortic aneurysm (AAA) represents a signiﬁ-
cant health problem, presenting in 5% to 7% of men above
the age of 65 years.1 Endovascular abdominal aortic aneu-
rysm repair (EVAR) is now routinely performed for the
treatment of an AAA, as early- and medium-term outcomes
have proven similar or even superior to open repair.2-4
Accurate identiﬁcation of preoperative risk factors allows
clinicians to provide better informed consent, take effective
preventive measures, and choose alternative treatment
strategies. In contrast to other types of surgical procedures,
risk-stratiﬁcation prior to EVAR has not been adequately
investigated.
Several studies have examined the association between
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://dx.doi.org/10.1016/j.jvs.2013.03.036various types of surgical procedures. Older studies have
concentrated on patients with moderately to severely
elevated serum creatinine dichotomized on the basis of
an arbitrary cut-off level.5,6 However, serum creatinine is
an imprecise measure of renal function. Several validated
formulas for estimation of glomerular ﬁltration rate
(GFR), a more accurate measure of renal function, have
subsequently been developed.7,8 The prognostic value of
preoperative renal function has gained signiﬁcant atten-
tion,9 and important studies have established the associa-
tion of preoperative estimated GFR (eGFR) with
morbidity and mortality after coronary artery bypass graft-
ing10,11 and peripheral vascular surgery.12
In two studies that aimed to identify predictors of
outcome after EVAR, increased serum creatinine was
shown to be associated with reduced medium-term
survival.5,6 Another study used creatinine clearance to cate-
gorize patients scheduled for EVAR in four arbitrarily
deﬁned groups and showed that individuals with the lowest
renal function (<45 mL/min) had signiﬁcantly lower
survival, but no difference was evident between the other
three groups.13 Additionally, a recent retrospective analysis
of 5811 elective EVARs showed that patients with a low
preoperative eGFR (Modiﬁed Diet in Renal Disease
formula) were at highest risk of 30-day mortality and
morbidity; no long-term follow-up was available.14 Overall,
the effect of renal function on outcome following EVAR879
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suboptimal measures of renal function and lack of long-
term follow-up.
Therefore, the aim of this prospective cohort study is to
examine the role of preoperative renal function, measured
with eGFR using the most contemporary formula (Chronic
Kidney Disease Epidemiology Collaboration [CKD-EPI]
equation)8 as a predictor of medium-term mortality and
cardiovascular outcome after EVAR.
METHODS
Study population. This is a prospective cohort study
including patients undergoing elective EVAR of an infrare-
nal AAA between January 2008 and April 2011 in a tertiary
referral center. Patients provided written informed consent
for their information to be recorded in a prospective
registry to investigate the effect of renal dysfunction
assessed by eGFR on outcome following EVAR. Patients
were eligible for EVAR if they had: an AAA diameter
>5 cm; AAA <5 cm with a rapidly increasing sac (>1 cm
per year). Patients with leaking, ruptured, infected, or
inﬂammatory aneurysms and patients with end-stage renal
disease receiving renal replacement therapy at baseline were
excluded. The study was approved by the institutional
ethics committee.
Study protocol. Baseline documentation of demo-
graphics and comorbidities was performed prior to
EVAR. All participants underwent a computed tomo-
graphic angiography. Blood samples were obtained prior
to any imaging requiring the administration of contrast.
A standard follow-up protocol, including a visit 30 days,
6 months, and 12 months after the operation and annually
thereafter, was used. Imaging at these intervals included
plain abdominal radiography and a computed tomographic
angiography at 6 months and 12 months and annually
thereafter. All data were prospectively entered in a purpose-
built electronic database.
Procedures. The following devices were used:
Anaconda (Vascutek, Inchinnan, Scotland), Gore Excluder
(Gore Medical, Flagstaff, Ariz), EndoFit (LeMaitre
Vascular, Burlington, Mass), Talent (Medtronic, Minneap-
olis, Minn), and Endurant (Medtronic). Indications and
speciﬁcations have been described elsewhere.15-18 All
procedures were performed in an operating theater under
general anesthesia and ﬂuoroscopic control, by adminis-
tering iopromide (Ultravist 300; Bayer Schering Pharma
AG, Berlin, Germany). For all patients, a standard renal
protection protocol was employed, which is the standard
practice for all patients undergoing EVAR in this depart-
ment. This included 1.2 g of oral N-acetylcysteine (Trebon
N; Uni-Pharma, Athens, Greece) administered 24 hours
prior to EVAR. The administration of any contrast for at
least 2 weeks and non-steroidal anti-inﬂammatory drugs for
at least 1 week prior to EVAR was avoided. Metformin was
discontinued 2 days prior to EVAR. For patients with
a preoperative eGFR >60 mL/min/1.73 m2, intravenous
ﬂuids administration (.9% saline, 2 mL/kg/hour) was
started on the day of the operation. In contrast, patientswith a baseline eGFR <60 mL/min/1.73 m2 were
admitted 1 day prior to EVAR and received intravenous
ﬂuids (.9% saline, 1.5 L/24 hours) for 24 hours in addition
to oral ﬂuids, until nil by mouth, when they were
commenced on 0.9% saline at a rate of 2 mL/kg/hour.
Bicarbonate infusion or any other modalities were not
used. Urinary catheterization and hourly urine output
measurements were routinely employed during and after
the procedure for at least 24 hours. In accordance with our
standard protocol for elective EVAR, aspirin and clopi-
dogrel were administered the day of the procedure. Aspirin
was discontinued on the 30th day, and clopidogrel was
continued as a life-long treatment.19 The patient was
ambulated as soon as possible and usually discharged on
day 2.
Study measurements and outcomes. Assessment of
renal function was based on eGFR, which was calculated
from standardized serum creatinine measurements, using
the CKD-EPI equation.8 All subjects were white Cauca-
sians. Serum creatinine measurements were obtained prior
to obtaining imaging that would require the administration
of contrast. Following calculation of baseline eGFR,
patients were divided in four separate groups: $90 mL/
min/1.73 m2, group 1; 60-89, group 2; 30-59, group
3; <30, group 4 (following the cut-offs of Chronic Kidney
Disease classiﬁcation of the National Kidney Foundation
[NKF], with the exception of Stage 5).20 All events were
classiﬁed according to the reporting standards for EVAR by
Chaikof et al.21 The composite end point in this analysis
consisted of death, nonfatal myocardial infarction, stroke,
and peripheral vascular complications. Peripheral vascular
complications were deﬁned as follows: any patient pre-
senting with symptomatic (rest-pain, tissue-loss, claudica-
tion) arterial disease with an ankle-brachial pressure
index <0.9 or relevant imaging that conﬁrms the presence
of arterial disease. Endoleak and device-related complica-
tions were recorded as per the aforementioned standards.
Statistical analysis. Analyses were performed using
the Statistical Package for Social Sciences Version 17.0
(SPSS Inc, Chicago, Ill). Continuous data are presented
as mean value 6 standard deviation and categorical data
are presented as absolute values and percentages. Baseline
differences between the study groups for continuous vari-
ables were evaluated using analysis of variance testing.
Differences with regards to categorical variables were eval-
uated using the Pearson c2 test. Kaplan-Meier curves were
constructed, and the log-rank test was applied to assess
differences between groups in survival and freedom from
composite end point during follow-up. Cox regression
analysis was used to assess the effects of renal function on
the composite end point and death after adjustment for
factors that were signiﬁcantly different between groups at
baseline. A P value level < .05 was considered statistically
signiﬁcant.
RESULTS
Baseline characteristics and intraprocedural events.
A total of 383 consecutive patients (32 females [8.3%]; mean
Table I. Baseline characteristics
Group 1 Group 2 Group 3 Group 4 P
Number of patients 173 110 80 20 –
Age, years 66 6 8 70 6 7 72 6 8 76 6 6 <.001
Female gender 10 (6) 8 (7) 13 (16) 1 (5) .04
AAA diameter, cm 5.9 6 1.2 6.3 6 1.2 6.5 6 1.8 6.8 6 1.6 .001
Smoking 118 (68) 86 (78) 58 (73) 16 (80) .2
Amount of contrast, mL 121 6 24 120 6 26 122 6 28 120 6 36 .5
Blood transfusion 16 10 4 2 .2
Duration, minutes 92 6 11 90 6 21 94 6 12 93 6 38 .6
Renal function indices
eGFR, mL/min/1.73 m2 126 6 28 73 6 8 48 6 8 21 6 6 <.001
Creatinine, mg/dL .8 6 .1 1.0 6 .1 1.3 6 .2 2.5 6 1.9 <.001
Comorbidities
Hypertension 112 (65) 90 (81) 68 (85) 16 (80) <.001
Diabetes 19 (11) 23 (21) 23 (29) 7 (35) .001
Previous MI 10 (6) 12 (11) 14 (18) 1 (5) .03
Previous stroke 3 (2) 12 (11) 12 (15) 1 (5) .001
Peripheral arterial disease 23 (13) 20 (18) 20 (25) 8 (40) .004
Statin use 82 (47) 71 (65) 55 (69) 14 (70) .001
AAA, Abdominal aortic aneurysm; eGFR, estimated glomular ﬁltration rate; MI, myocardial infarction.
Continuous data presented as mean 6 standard deviation and categoric data as number (%).
Table II. Events of interest during follow-up
Group 1, No. (%) Group 2, No. (%) Group 3, No. (%) Group 4, No. (%) P
Number of patients 173 110 80 20 –
Nonfatal MI 1 (.5) 3 (3) 5 (6) 6 (30) <.001
Nonfatal stroke 0 0 8 (10) 1 (5) <.001
Peripheral vascular complication 1 (.5) 4 (4) 0 2 (10) .09
Claudication, noncritical 1 3 0 2 –
Peripheral embolization 0 1 0 0 –
Death 1 (.5) 2 (2) 10 (12) 7 (35) <.001
Composite end point 3 (2) 9 (8) 23 (28) 16 (80) <.001
Endoleak type 1 11 (6) 5 (5) 3 (4) 1 (5) .5
MI, Myocardial infarction.
Composite end point consists of: death, nonfatal MI, nonfatal stroke, and peripheral vascular complication.
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who underwent elective EVAR for an infrarenal AAA and
met the exclusion criteria were included. None of the
patients were symptomatic. Baseline characteristics of the
four eGFR groups are shown in Table I. The amount of
contrast medium used and the duration of the procedure
were not signiﬁcantly different between groups (P ¼ .54 and
P ¼ .62, respectively). In one case (Anaconda device -
repositionable), the oriﬁce of one renal artery was uninten-
tionally covered, but this was recognized, and the device was
immediately repositioned. Completion angiogram disclosed
no further complications. A total of 32 patients (8%)
required a blood transfusion, all within the ﬁrst 24 hours;
this did not differ signiﬁcantly between groups (P ¼ .2).
No intraprocedural deaths or conversion to open-repair
occurred. One male patient (10 cm AAA) developed
disseminated intravascular coagulation (DIC) within 8 hours
of the procedure and died (baseline eGFR, 47 mL/min/
1.73 m2), despite successful deployment. This patient
developed bleeding from the access site that was easilycontrolled intraoperatively and required a transfusion of
4 units of packed red cells. During his stay in intensive
treatment unit, he developed DIC, with a raise in
prothrombin time, partial thromboplastin time, and a drop
in platelet count; computed tomography imaging did not
disclose any device-related complications. Post-mortem
examination revealed no aneurysm-related complications.
Periprocedural (#30 days) events. Four patients
(1%) died during this period, one due to DIC, two due to
a myocardial infarction (MI), and one due to a stroke. All
four patients who died had a preoperative eGFR <59 mL/
min/1.73 m2. Periprocedural (#30 days) mortality rates
were: group 1, 0%; group 2, 0%; group 3, 2.5% (two
patients); and group 4, 10% (two patients). Three patients
developed a nonfatal stroke, one developed a nonfatal MI,
and three patients developed iliac-limb thrombosis, having
to undergo a secondary procedure (femoro-femoral bypass).
Overall, all patients who developed a complication as per the
composite end point #30 days of the procedure had an
eGFR <59 mL/min/1.73 m2. Additionally, six patients
Fig 1. Kaplan-Meier curve for freedom from composite end point
and number of patients surviving free from complications as per
end point during follow-up.
Fig 2. Kaplan-Meier curve for survival and number of patients
surviving during follow-up.
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with antibiotics. Three patients (.8%) developed a type 1
endoleak, which resolved with a secondary endovascular
procedure.
Events during follow-up. Mean follow-up was 34 6
12 months. Results are summarized in Table II.
Throughout follow-up, a total of 20 deaths occurred
(5.2%), 12 due to an MI, 4 due to sepsis, 1 due to cancer
undiagnosed at the time of EVAR (death occurred
18 months after the repair), 1 due to bowel ischemia, 1 due
to stroke, and 1 due to DIC. Additionally, 15 nonfatal MIs
(3.9%), 9 nonfatal strokes (2.3%), and 7 peripheral vascular
complications (1.8%) occurred. None of the patients who
died had developed type 1 endoleak or other device-related
complication. As shown in Table II, in univariate analysis,
the episodes of death (P < .001) and the composite end
point (P < .001) were signiﬁcantly more frequent with
decreasing eGFR. Cumulative univariate analysis of groups
1 and 2 vs groups 3 and 4 (patients with eGFR $60 vs
patients with eGFR <59) disclosed that those with an
eGFR <59 had a higher incidence of complications as per
the composite end point (39% vs 4%; P < .001) and higher
mortality (17% vs 1%; P < .001).
Cumulative freedom from the composite end point at
36 months for the four eGFR groups was as follows: group
1, 99%; group 2, 96%; group 3, 85%; and group 4, 6% (log-
rank, P < .001; Fig 1). Similarly, cumulative survival was
99% for group 1, 98% for group 2, 90% for group 3, and
25% for group 4 (log-rank, P < .001; Fig 2). Patients
with a baseline eGFR <59 also had signiﬁcantly lower
cumulative freedom from the composite end point (94%
vs 27%; log-rank, P < .001) and signiﬁcantly lower cumu-
lative survival (99% vs 48%; log-rank, P < .001) compared
with those with an eGFR $60. Cox regression, adjusted
for factors that differed in univariate analysis, revealed
that higher eGFR by 1 mL/min/1.73 m2 at baseline wasassociated with lower risk for the composite end point
(hazard ratio, 0.95; 95% conﬁdence interval, 0.94-0.97;
P < .001) and death (hazard ratio, 0.94; 95% conﬁdence
interval, 0.92-0.97; P < .001). Relevant results are summa-
rized in Tables III and IV.
DISCUSSION
This prospective cohort study aimed to examine the
role of preoperative renal function (eGFR using the
CKD-EPI equation) as a predictor of mortality, cardiovas-
cular outcomes, and other complications after EVAR. The
main ﬁndings were that freedom from the composite end
point, as well as survival at medium-term decreased signif-
icantly and progressively with advancing stages of CKD.
Even a slight increment in baseline eGFR (1 mL/min/
1.73 m2) was associated with signiﬁcantly lower risk of
the composite end point and death.
Traditionally, serum creatinine has been used in studies
assessing the predictive role of preoperative renal function
for various types of operations.9 However, serum creatinine
is insensitive to mild and moderate degrees of renal impair-
ment, because it depends on several predictors of muscle
mass. Creatinine concentration will rise out of normal
range only when over half of renal function is lost.9
Thus, several formulas have been developed to provide
more accurate estimates of renal function. One of the
earlier equations was that of Cockcroft and Gault,22
providing an estimate of creatinine clearance. The formula
carries some inherent limitations of creatinine metabolism
and overestimates GFR for most patients; it also requires
computation of body surface area and adjustment to
1.73 m2 before comparison to normal values. The equation
of the Modiﬁcation of Diet in Renal Disease (MDRD)
study7 provided an accurate estimate of GFR and was the
basis of the CKD classiﬁcation proposed by the NKF in
the United States.20 This equation was perhaps the one
Table III. Multivariate regression analysis for the
composite end point (death, nonfatal myocardial
infarction, stroke, and peripheral vascular complications)
during follow-up
Parameter
Hazard
ratio
95% conﬁdence
interval for
hazard ratio P
Age, per year increase 1.02 .98 1.06 .4
Gender .75 .31 1.84 .5
AAA diameter, per 1-cm
increase
1.12 .95 1.32 .2
eGFR, per mL/min/1.73 m2 .95 .94 .97 <.001
Hypertension 1.24 .52 2.96 .6
Diabetes 1.10 .59 1.98 .8
MI .92 .39 2.17 .8
Stroke 2.67 1.32 5.43 .007
Peripheral arterial disease 1.20 .66 2.19 .5
Statin use .76 .39 1.51 .4
AAA, Abdominal aortic aneurysm; eGFR, estimated glomerular ﬁltration
rate; MI, myocardial infarction.
Table IV. Multivariate regression analysis for all-cause
mortality during follow-up
Parameter
Hazard
ratio
95% conﬁdence
interval for
hazard ratio P
Age, per year increase 1.04 .96 1.12 .3
Gender 1.04 .21 5.20 .9
AAA diameter, per 1-cm
increase
1.20 .96 1.48 .1
eGFR, per mL/min/1.73 m2 .94 .92 .97 <.001
Hypertension 5.63 .67 47.17 .1
Diabetes 1.40 .53 3.69 .5
MI 1.30 .41 4.16 .7
Peripheral arterial disease 1.18 .45 3.15 .7
Stroke 4.89 1.51 15.84 .008
Statin use .36 .13 1.06 .06
AAA, Abdominal aortic aneurysm; eGFR, estimated glomerular ﬁltration
rate; MI, myocardial infarction.
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estimation of eGFR was recently developed and appeared
to perform with greater accuracy than the MDRD
formula.8 Studies from different population settings sug-
gested that it achieves better classiﬁcation of CKD, as
well as more accurate risk-stratiﬁcation of patients at high
risk for cardiovascular disease, such as those undergoing
EVAR.25-28 As a result, we attempted to assess the perfor-
mance of eGFR calculated using the CKD-EPI formula as
a predictor of cardiovascular outcome in a cohort of
patients undergoing EVAR.
Several studies have assessed the role of preoperative
eGFR instead of serum creatinine as a predictor of
outcome. In patients undergoing coronary artery bypass
grafting, the risk of death and morbidity increased signiﬁ-
cantly at levels <60 mL/min/1.73 m2 and were very
prominent at eGFR values <30 mL/min/1.73 m2.11,29
Similar trends have been documented in peripheral vascular
surgery.12 Additionally, even subtle changes in pre-
operative eGFR have been found to inﬂuence long-term
outcome30 and predict outcome more accurately even
when compared with classical cardiovascular risk factors.12
Subsequently, it was suggested that all patients undergoing
vascular or cardiac surgery should have their eGFR assessed
as part of the preoperative evaluation.9
Two studies have examined renal function by terms of
serum creatinine concentration in predicting medium-term
outcome after EVAR. Boult et al5 examined survival in
961 individuals from the National Australian Registry
who had elective or semi-urgent EVAR. Patients were
categorized in three groups on the basis of serum crea-
tinine (ie, <120 mmol/L, $120 and <160 mmol/L, and
>160 mmol/L), with 5-year survival rate falling from
71% to 58% and 40%, respectively. However, as the
authors admit, the study is limited by absence of formal
GFR calculation; most importantly, it can be argued that
given the age of the cohort many individuals with serumcreatinine <120 mmol/L would have a GFR well below
60 mL/min/1.73 m2. Similarly, a retrospective study of
197 patients undergoing elective EVAR6 has shown that
renal failure, deﬁned as serum creatinine >120 mmol/L
(P ¼ .0048), and increased creatinine (P ¼ .0022) was
associated with decreased survival at 5 years. Again,
improper deﬁnition of “renal failure” and inaccuracy of
renal function categorization is obvious, as only 1 out of
21 patients with serum creatinine >120 mmol/L actually
had “renal failure” and required dialysis.
Azizzadeh et al13 studied the effect of preoperative
renal function in a retrospective cohort of 398 patients
who underwent EVAR. They divided patients into four
groups, based on preoperative creatinine clearance (Cock-
croft-Gault equation) as follows: I (7 to 45 mL/min), II
(45 to 60), III (61 to 79), and IV ($80). Quartile I fared
signiﬁcantly worse than the other three during the ﬁrst 30
postoperative days and over a follow-up of 48 months.
Survival curves for quartiles II to IV were statistically indis-
tinguishable, with quartile II running tangential to the two
higher quartiles after the perioperative period. This study,
however, has two major limitations; ﬁrst, although the
authors use the term “eGFR” throughout the manuscript
(and even the title), they have actually categorized patients
by calculated creatinine clearance (not corrected for body
surface), which is clearly a different estimate from eGFR.
Most importantly, the selected categorization of patients
based on renal function has nothing in common with the
CKD classiﬁcation of the NKF20; thus, any comparisons
and extrapolation of data to clinical CKD groups cannot
be made. In the present analysis we also attempted to
compare results between those with an eGFR $60 and
those with an eGFR <60 mL/min/1.73 m2. Survival
and advent of complications as per the end point were
signiﬁcantly inferior for those with an eGFR <60, similar
to what was previously suggested by Azizzadeh et al.13
Our study has strengths and limitations. We have calcu-
lated eGFR using the CKD-EPI equation, which appears
to be the most accurate formula for this purpose. We
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proposed from the NKF (with the exception of Stage 5,
as individuals with end-stage renal disease requiring dialysis
were excluded), which is the most widely used classiﬁcation
of CKD. However, we did not include preoperative urine
albumin measurements, which is required for CKD staging
in Stages 1 and 2. A standard renal protection protocol
prior to the procedure was employed for all patients.
Further, a standardized follow-up was carefully performed.
However, serum creatinine levels immediately after the
procedure and 48 hours after the procedure (when contrast
induced nephropathy is most likely to develop) were not
available for many of the patients, and therefore, it was
not possible to assess the effect of preoperative renal
dysfunction on postoperative acute kidney injury. The
four study groups also differed in terms of AAA size
(Table I); however, the amount of contrast medium used
and the procedural time did not differ signiﬁcantly, and
adjusted analyses were performed. Also, as expected,
increasing stage of CKD was associated with signiﬁcantly
more comorbidities; however, we have adjusted for these
in our multivariate analyses. Finally, the mean duration of
follow-up was 2.6 years; thus, the effect over longer-term
periods needs to be further explored.
Overall, this study suggests that decreased eGFR
calculated using the CKD-EPI equation is associated
with reduced survival and increased risk of complica-
tions following EVAR. Groups 3 and 4 were most likely
to develop cardiovascular morbidity and death (eGFR
<60 mL/min/1.73 m2), and in fact, an increase in
eGFR of 1 mL/min/1.73 m2 was independently associ-
ated with lower risks of morbidity and mortality. Measure-
ment of renal function by means of eGFR is a simple
risk-stratifying tool that may help identify patients at
high-risk for cardiovascular complications, who would
beneﬁt from aggressive preventative measures. These
include aggressive preoperative and postoperative rehydra-
tion, as even a small rise in eGFR can be beneﬁcial, use of
adjuncts such as N-acetylcysteine and sodium bicarbonate
to prevent further decline in eGFR perioperatively,31
preoperative optimization of cardiovascular parameters,
closer perioperative monitoring, and better control of asso-
ciated risk factors (hyperlipidemia, hypertension, smoking)
over the longer term.AUTHOR CONTRIBUTIONS
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